MX2021006527A - Compuesto macrociclico y su uso. - Google Patents

Compuesto macrociclico y su uso.

Info

Publication number
MX2021006527A
MX2021006527A MX2021006527A MX2021006527A MX2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A
Authority
MX
Mexico
Prior art keywords
disease
kidney
mitochondrial
inflammatory
formula
Prior art date
Application number
MX2021006527A
Other languages
English (en)
Inventor
Ayumu Niida
Shigemitsu Matsumoto
Naoyoshi Noguchi
Toshitake Kobayashi
Tsuyoshi Maekawa
Satoshi Sasaki
Ryoma Hara
Minoru Ikoma
Hideto Fukushi
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of MX2021006527A publication Critical patent/MX2021006527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto representado por la fórmula (I): (ver Fórmula) donde cada símbolo es como se lo define en la presente, o una sal de éste, que presenta actividad de activación sobre NRF2, del cual se espera que sea útil como agente preventivo o terapéutico para enfermedades asociadas al estrés oxidativo, particularmente, enfermedades hepáticas (por ejemplo, esteatohepatitis no alcohólica (ENA)), enfermedades cardiovasculares (por ejemplo, insuficiencia cardíaca o hipertensión arterial pulmonar), enfermedades pulmonares (por ejemplo, enfermedad pulmonar obstructiva crónica (EPOC)), enfermedades renales (por ejemplo, enfermedad renal crónica (ERC) o lesión renal aguda (LRA)), enfermedades en el sistema nervioso central (por ejemplo, enfermedad de Parkinson), enfermedades mitocondriales (por ejemplo, ataxia motora de Friedreich o miopatía mitocondrial), enfermedades inflamatorias (por ejemplo, esclerosis múltiple (EM) o enfermedad inflamatoria intestinal (EII)), enfermedades en las células falciformes, cánceres o similares.
MX2021006527A 2018-12-05 2019-12-04 Compuesto macrociclico y su uso. MX2021006527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
MX2021006527A true MX2021006527A (es) 2021-07-21

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006527A MX2021006527A (es) 2018-12-05 2019-12-04 Compuesto macrociclico y su uso.

Country Status (17)

Country Link
US (1) US11518763B2 (es)
EP (1) EP3890738A4 (es)
JP (1) JP2022510736A (es)
KR (1) KR20210099622A (es)
CN (1) CN113164468A (es)
AR (1) AR117251A1 (es)
AU (1) AU2019391942B2 (es)
BR (1) BR112021010704A2 (es)
CA (1) CA3121952A1 (es)
CL (1) CL2021001451A1 (es)
CO (1) CO2021007304A2 (es)
MX (1) MX2021006527A (es)
PH (1) PH12021551262A1 (es)
SG (1) SG11202105125XA (es)
TW (1) TWI820266B (es)
UA (1) UA127872C2 (es)
WO (1) WO2020116660A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108534A1 (en) 2018-08-20 2020-02-27 Janssen Pharmaceutica Nv Inhibitors of keap1-nrf2 protein-protein interaction
PE20231363A1 (es) * 2020-09-14 2023-09-05 Sanofi Sa Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029393T2 (en) 2010-08-31 2017-03-28 Bionure Farma S L Neurotrophin receptor agonists and their use as medicaments
ES2724275T3 (es) 2013-06-21 2019-09-09 Karyopharm Therapeutics Inc 1,2,4-triazoles como moduladores del transporte nuclear y usos de los mismos
CR20160272A (es) * 2013-12-18 2016-08-16 Glaxosmithkline Ip Dev Ltd REGULADORES DE Nrf2
EP3307719A1 (en) 2015-06-15 2018-04-18 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
JP6786527B2 (ja) 2015-06-15 2020-11-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター
CN108112251B (zh) 2015-06-15 2021-03-05 葛兰素史克知识产权发展有限公司 Nrf2调节剂
CA2995325A1 (en) 2015-08-12 2017-02-16 Mochida Pharmaceutical Co., Ltd. Isothiazole derivative
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
EP3551620A1 (en) 2016-12-12 2019-10-16 GlaxoSmithKline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
US11117905B2 (en) 2016-12-14 2021-09-14 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as NRF2 activators
JP2020502136A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのビスアリールアミド
ES2848699T3 (es) 2016-12-14 2021-08-11 Glaxosmithkline Ip Dev Ltd Compuestos de 3-oxo-1,4-diazepinilo como activadores de NRF2
ES2908941T3 (es) 2016-12-15 2022-05-04 Glaxosmithkline Ip Dev Ltd Triazoles unidos a éter como reguladores de NRF2
CA3044773A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 activators
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
EP3573968A1 (en) * 2017-01-30 2019-12-04 Biogen MA Inc. Nrf2 activator
WO2018140738A1 (en) 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf 2 activator
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
EP3890738A4 (en) 2022-08-17
JP2022510736A (ja) 2022-01-27
EP3890738A1 (en) 2021-10-13
BR112021010704A2 (pt) 2021-08-24
UA127872C2 (uk) 2024-01-31
AU2019391942A1 (en) 2021-06-03
AU2019391942B2 (en) 2024-03-21
SG11202105125XA (en) 2021-06-29
CA3121952A1 (en) 2020-06-11
AR117251A1 (es) 2021-07-21
US11518763B2 (en) 2022-12-06
US20220119391A1 (en) 2022-04-21
CN113164468A (zh) 2021-07-23
TW202039494A (zh) 2020-11-01
WO2020116660A1 (en) 2020-06-11
KR20210099622A (ko) 2021-08-12
CO2021007304A2 (es) 2021-06-21
CL2021001451A1 (es) 2021-12-24
TWI820266B (zh) 2023-11-01
PH12021551262A1 (en) 2021-10-25

Similar Documents

Publication Publication Date Title
PH12021551262A1 (en) Macrocyclic compound and use thereof
MX2015001115A (es) Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal.
PH12015502012A1 (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
SG10201902370QA (en) Compositions and methods of use of phorbol esters
PH12018500261A1 (en) Azole benzene derivative
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
PE20211595A1 (es) Compuestos de 2,6-diaminopiridina
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
BR112021023153A2 (pt) Compostos de pirazol dissubstituídos como inibidores de ceto-hexoquinase
MX361925B (es) Medicamento inhalable que comprende tiotropio.
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2022004744A (es) Composiciones que comprenden 2'-fucosil-lactosa para prevenir el asma.
BR112015024897A2 (pt) derivado de fenila
NZ590454A (en) Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology
IN2014DN00185A (es)
SA515360085B1 (ar) مشتق ودواء بيريدين
MX2014005165A (es) Proceso novedoso para la preparacion de acilguanidinas y aciltioureas.
PH12015502264A1 (en) Pyrazole derivative
Althaqfi et al. Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period
WO2018191379A3 (en) CHITINASE DELIVERY IN RESPIRATORY TRACT TO TREAT INFLAMMATORY AND AGE-RELATED LUNG FIBROSIS
Grubnik et al. Complex treatment of patients with cirrhosis complicated by variceal bleeding
UA102971U (ru) Способ коррекции метаболических нарушений в легких крыс при ожоговой болезни
Dean et al. A52 PRECLINICAL TRIALS IN PULMONARY HYPERTENSION MODELS: NOVEL TARGETS AND DELIVERY: Effect Of Metformin On Pulmonary Hypertension In The Sugen/hypoxic Rat Model: Possible Role For Aromatase
Mittal Dopamine/norepinephrine
Terasaki et al. B63 MOLECULAR INSIGHTS INTO LUNG CANCER II: Hydrogen-Supplemented Drinking Water Protects Against Naphthalene-Gefitinib Induced Lung Injury From Inflammation-Associated Oxidative Stress